Report error Found 210 of ic50 data for polymerid = 1047
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.300nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.400nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.600nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.700nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.900nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.60nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.90nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.40nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.5nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.70nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.80nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.10nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Human)
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.30nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair